1
|
Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer 2016; 4:81. [PMID: 27891227 PMCID: PMC5109802 DOI: 10.1186/s40425-016-0180-7] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Accepted: 10/20/2016] [Indexed: 12/18/2022] Open
Abstract
Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number of new agents have been approved for RCC, several of which attack tumor angiogenesis by inhibiting vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR), as well as tumor metabolism, inhibiting the mammalian target of rapamycin (mTOR). Additionally, a new class of immunotherapy agents, immune checkpoint inhibitors, is emerging and will play a significant role in the treatment of patients with RCC. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a Task Force, which met to consider the current role of approved immunotherapy agents in RCC, to provide guidance to practicing clinicians by developing consensus recommendations and to set the stage for future immunotherapeutic developments in RCC.
Collapse
Affiliation(s)
- Brian I. Rini
- Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Cleveland, OH 44195 USA
| | - David F. McDermott
- Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, 10 Highfield Circle, Milton, MA 02186 USA
| | - Hans Hammers
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans St, Baltimore, MD 21287 USA
| | - William Bro
- Kidney Cancer Association, PO Box 4668 #38269, Chicago, IL 60680 USA
| | - Ronald M. Bukowski
- Cleveland Clinic Taussig Cancer Institute, 1 Clinic Center, Cleveland, OH 44195 USA
| | | | - Jo Faba
- Patient and Patient Advocate, Cleveland, USA
| | - Robert A. Figlin
- Cedars-Sinai Medical Center, 8700 Beverly Blvd., Saperstein Critical Care Tower, 1S28, Los Angeles, CA 90048 USA
| | - Thomas Hutson
- Charles A. Sammons Cancer Center, Baylor University Medical Center, 3410 Worth Street, Suite 400, Dallas, TX 75254, USA
| | - Eric Jonasch
- M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | | | | | - Thomas Olencki
- The Ohio State University Medical Center, 320 W. 10th Avenue, Columbus, OH 43210, USA
| | - Allan J. Pantuck
- UCLA Institute of Urologic Oncology, 66-124 Center for Health Sciences, Los Angeles, CA 90095, USA
| | - David I. Quinn
- Kenneth J. Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Ave Suite 3451, Los Angeles, CA 90033, USA
| | - Virginia Seery
- Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, 10 Highfield Circle, Milton, MA 02186 USA
| | - Martin H. Voss
- Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
| | - Christopher G. Wood
- M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Laura S. Wood
- Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Cleveland, OH 44195 USA
| | - Michael B. Atkins
- Georgetown-Lombardi Comprehensive Cancer Center, 3970 Reservoir Road, NW, Research Building, Room E501, Washington, DC 20057, USA
| |
Collapse
|
2
|
Cresswell J, Laniado M, Sinclair A, Smith D, Venn S, Williams S, Brewster S. Advances in urology 2014–2015. JOURNAL OF CLINICAL UROLOGY 2016. [DOI: 10.1177/2051415816640193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
It has become customary that a session is held at the British Association of Urological Surgeons (BAUS) annual meeting, wherein the most important advances in the major urological sub-specialities are summarised by British opinion leaders for the benefit of the core of urologists. It gives us pleasure to present in this paper the topics covered at the BAUS meeting in June 2015, in Manchester, UK.
Collapse
Affiliation(s)
- Jo Cresswell
- James Cook University Hospital, Middlesbrough, UK
| | - Marc Laniado
- Frimley Park National Health Service (NHS) Trust, Frimley, UK
| | | | | | - Suzie Venn
- St Richards Hospital, Western Sussex Hospitals Foundation Trust, UK
| | - Simon Williams
- Derby Teaching Hospitals NHS Foundation Trust, Derby, UK
| | - Simon Brewster
- Department of Urology, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UK
| |
Collapse
|